<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30349" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>3,4-Methylenedioxymethamphetamine (MDMA) Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Figurasin</surname>
            <given-names>Rick</given-names>
          </name>
          <aff>Newark Beth Israel Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Vincent R.</given-names>
          </name>
          <aff>Northwell Health/Zucker School of Medicine at Hofstra School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maguire</surname>
            <given-names>Nicole J.</given-names>
          </name>
          <aff>Newark Beth Israel Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rick Figurasin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vincent Lee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nicole Maguire declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30349.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>MDMA, or&#x000a0;3,4-methylenedioxymethamphetamine, is a synthetic amphetamine derivative&#x000a0;known as a recreational drug since the 1980s by street names like "Ecstasy," "Molly," and "XTC." The entactogenic properties foster euphoria, memory retrieval, and enhanced sensory perception. This course sheds light on&#x000a0;clinical aspects of MDMA use, emphasizing its potential life-threatening impact on cardiovascular, neurological, renal, and hepatic systems.</p>
        <p>Participants will&#x000a0;gain&#x000a0;the&#x000a0;skills to&#x000a0;assess, manage, and&#x000a0;recognize adverse effects&#x000a0;to intervene promptly. Beyond individual competencies, the course underscores the significance of an interprofessional care approach. A dynamic blend of case studies, expert insights, and practical scenarios equips learners to navigate MDMA-related emergencies with precision. The course highlights the pivotal role of&#x000a0;addressing MDMA-induced morbidity, emphasizing effective communication and shared decision-making. By bridging the&#x000a0;practice&#x000a0;gap collectively, clinicians and&#x000a0;allied healthcare professionals will be empowered to deliver optimal care, improving patient outcomes in instances of MDMA-related emergencies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the acute&#x000a0;symptoms and signs&#x000a0;of MDMA toxicity, especially in emergency settings.</p></list-item><list-item><p>Apply&#x000a0;current, evidence-based treatments&#x000a0;for patients with&#x000a0;MDMA toxicity.</p></list-item><list-item><p>Implement&#x000a0;the appropriate diagnostic tests for a&#x000a0;patient with&#x000a0;MDMA toxicity.</p></list-item><list-item><p>Collaborate with interprofessional team members, including medical toxicologists, pharmacists, and poison&#x000a0;control&#x000a0;centers, to provide efficient, comprehensive, and coordinated care for the&#x000a0;MDMA toxic patient.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30349&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30349">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30349.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>MDMA, or&#x000a0;3,4-methylenedioxymethamphetamine, is a synthetic amphetamine derivative&#x000a0;known as a recreational drug since the 1980s by street names such as "Ecstacy," "E," "Molly," "XTC," "X," "Beans," and "Adams." The entactogenic properties foster euphoria, memory retrieval, and enhanced sensory perception.&#x000a0;The synthetic derivative of amphetamine was first developed in 1912, leading to public introduction in the 1960s and recreational drug use in the 1980s.</p>
        <p>MDMA is widely considered part of the psychoactive group of substances called entactogens (Greek roots meaning "touching within"). As an entactogen, MDMA promotes euphoria, retrieval of repressed memories, feelings of closeness, empathy, sexuality, and communication.&#x000a0;Under the Controlled Substance Act of 1970, the U.S. Food and Drug Administration (FDA) placed MDMA in Schedule I in 1985, meaning it&#x000a0;has a high potential for abuse and no currently accepted medical use. However, a recent&#x000a0;landmark double-blind, placebo-controlled phase 3 clinical trial&#x000a0;found that MDMA may be highly effective in treating&#x000a0;posttraumatic stress disorder (PTSD) in combination with psychotherapy.<xref ref-type="bibr" rid="article-30349.r1">[1]</xref>&#x000a0;As a result, the use of MDMA for PTSD treatment is in the process of FDA approval.</p>
        <p>MDMA is mainly&#x000a0;available&#x000a0;in colorful tablets with logo brands but may also be in capsule, powder, and liquid forms. Its use mainly involves swallowing tablets, but sometimes, it may be crushed and insufflated. Its effects on the cardiovascular, neurological, renal, and hepatic systems can be life-threatening, and recognizing its toxicity is essential&#x000a0;for clinicians in emergency settings.<xref ref-type="bibr" rid="article-30349.r2">[2]</xref><xref ref-type="bibr" rid="article-30349.r3">[3]</xref></p>
      </sec>
      <sec id="article-30349.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The potential for MDMA toxicity exists with&#x000a0;each ingestion, substantiating its designation as a Schedule I drug. MDMA is commonly ingested in tablet form; however, the tablet may be crushed&#x000a0;and ingested intranasally. Recreational doses of MDMA can vary significantly from 50 mg to 200 mg per tablet. However, analysis of compounds sold as ecstasy&#x000a0;or molly has revealed&#x000a0;mixed composition with other substances, including methyl diethanolamine (MDEA, also known as "eve"), 3,4-methylenedioxyamphetamine (MDA, also known as "sally"), ephedrine, ketamine, paracetamol, inactive substitutes, some&#x000a0;producing hemodynamic effects.<xref ref-type="bibr" rid="article-30349.r4">[4]</xref><xref ref-type="bibr" rid="article-30349.r5">[5]</xref><xref ref-type="bibr" rid="article-30349.r6">[6]</xref>&#x000a0;As a result, significant adverse effects and toxicity can occur with one-time or first-time ingestion due to the&#x000a0;unknown dosage and composition of the drug.<xref ref-type="bibr" rid="article-30349.r7">[7]</xref></p>
        <p>MDMA&#x000a0;is commonly&#x000a0;used with other recreational&#x000a0;drugs, which can potentiate or antagonize&#x000a0;the toxic&#x000a0;effects on the&#x000a0;neurological and cardiovascular systems.<xref ref-type="bibr" rid="article-30349.r3">[3]</xref><xref ref-type="bibr" rid="article-30349.r8">[8]</xref>&#x000a0;Combined with physical activity in a hot, humid environment, this compounding effect can lead to significant hyperthermia, dehydration, and hyponatremia, mimicking the effects of heat stroke in many cases.<xref ref-type="bibr" rid="article-30349.r9">[9]</xref></p>
      </sec>
      <sec id="article-30349.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Trends in MDMA use&#x000a0;are well documented throughout the years, with user age ranging from the 8th grade to the&#x000a0;collegiate&#x000a0;level and adulthood. A review of epidemiological data revealed a significant increase in usage between the 1990s and early 2000s. For example, lifetime&#x000a0;MDMA use on one college campus was found to increase from 16% to 24% between the years 1986 and 1990, while a national sample of college students saw a 69% increase between the years 1997 and 1999.<xref ref-type="bibr" rid="article-30349.r10">[10]</xref>&#x000a0;From 1999 to 2000, lifetime use among 8th graders increased from 2.7% to 4.3%, while this increase was significantly&#x000a0;greater in 12th graders (8%-11%). Also, emergency room visits in the United States increased from 253 to 4511 between 1994 and 2000.<xref ref-type="bibr" rid="article-30349.r11">[11]</xref>&#x000a0;A 2002 Monitoring the Future study found that 12.7% of United States college students had used ecstasy once in their lifetime. The 2002 National Survey of Drug Use and Health found a greater than 200% increase in&#x000a0;MDMA use by adults 18 to 25 years old from 1996 to 2002.<xref ref-type="bibr" rid="article-30349.r10">[10]</xref></p>
        <p>While the number of users increased significantly from the early 1990s and 2000s, the number of new users varied from 2002 to 2007. Surveys found a decrease in users from 1.2 million in 2002 to 642,000 in 2003, then up to 860,000 from 2006 to 2007.<xref ref-type="bibr" rid="article-30349.r12">[12]</xref>&#x000a0;In 2011, data from the National Survey on Drug Use and Health estimated about 14.5 million users aged 12 or older had used&#x000a0;MDMA at least once in their lifetime, with approximately 900,000 using it for the first time in 2011. This number increased to 17 million in 2013, with the highest use among&#x000a0;young adults aged 18 to 25. Though MDMA&#x000a0;use is less prevalent than&#x000a0;cannabis, opioid, and other amphetamine use in the United States and worldwide, it remains a significant public health concern due to its adverse effect profile.<xref ref-type="bibr" rid="article-30349.r8">[8]</xref></p>
      </sec>
      <sec id="article-30349.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The difference between&#x000a0;MDMA and other amphetamines is due to the attachment of the methylenedioxy group, which is structurally similar to the psychedelic hallucinogen mescaline. MDMA is a compound with characteristics of both amphetamines and hallucinogens.<xref ref-type="bibr" rid="article-30349.r13">[13]</xref>&#x000a0;It primarily increases the concentration of norepinephrine, dopamine, and serotonin within the synaptic cleft. MDMA inhibits the reuptake of the neurotransmitter serotonin (5-HT) and stimulates its carrier-mediated release&#x000a0;into synapses. Like other amphetamine analogs, MDMA also inhibits monoamine oxidase activity, which further contributes to increased serotonin levels (in addition to dopamine and norepinephrine). Like serotonin, MDMA affects dopamine transporters by promoting release and inhibiting reuptake. The binding of noradrenergic, histaminergic, and muscarinic receptors contributes to the noradrenaline, histamine, gamma-aminobutyric acid (GABA), and acetylcholine effects of the drug. The&#x000a0;activity&#x000a0;on&#x000a0;post-synaptic receptors plays a role in mood, thermoregulation, and the autonomic nervous system.<xref ref-type="bibr" rid="article-30349.r5">[5]</xref><xref ref-type="bibr" rid="article-30349.r6">[6]</xref></p>
        <p>The desired effects of the drug include sympathomimetic arousal, sensual enhancement, feelings of euphoria, and emotional closeness to others. Other effects include nausea, trismus, and bruxism. These effects are attributable to the increased circulation of dopamine and serotonin. Blood pressure and heart rate elevations are secondary to the adrenergic effects of increased circulating norepinephrine acting on &#x003b1;, &#x003b2;-1, and &#x003b2;-2 receptors.<xref ref-type="bibr" rid="article-30349.r14">[14]</xref><xref ref-type="bibr" rid="article-30349.r15">[15]</xref></p>
        <p>In addition to its effects on neurotransmitters, MDMA&#x000a0;increases the levels of arginine vasopressin (antidiuretic hormone), leading to fluid retention. This effect, coupled with excessive water intake, is implicated in the development of life-threatening hyponatremia and coma.<xref ref-type="bibr" rid="article-30349.r16">[16]</xref></p>
      </sec>
      <sec id="article-30349.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>When ingested,&#x000a0;MDMA is&#x000a0;readily absorbed&#x000a0;through the&#x000a0;gastrointestinal tract&#x000a0;with an onset between 20 minutes and 1 hour and peak concentrations occurring at 2 hours. MDMA is primarily metabolized&#x000a0;hepatically through&#x000a0;CYP2D6. The elimination half-life of MDMA is moderately slow at&#x000a0;about 8 hours. MDMA takes&#x000a0;about 40 hours (ie,&#x000a0;5 half-lives) to achieve over 95% drug clearance. Since some metabolites of MDMA are pharmacologically active, such as MDA, the duration of clinical effects may continue&#x000a0;after clearance from the body.<xref ref-type="bibr" rid="article-30349.r6">[6]</xref><xref ref-type="bibr" rid="article-30349.r17">[17]</xref><xref ref-type="bibr" rid="article-30349.r18">[18]</xref></p>
      </sec>
      <sec id="article-30349.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation of acute MDMA toxicity is similar to amphetamines and includes tachycardia, hypertension, dysrhythmias, anxiety, agitation, hallucinations, seizures, mydriasis, diaphoresis, and hyperthermia. However, MDMA has less stimulant&#x000a0;and more serotonergic effects compared to amphetamines and methamphetamines.<xref ref-type="bibr" rid="article-30349.r19">[19]</xref>&#x000a0;At&#x000a0;low doses, adverse effects include increased muscle activity, such as bruxism, restless legs, jaw clenching, hyperactivity, insomnia, difficulty concentrating, and feelings of restlessness.<xref ref-type="bibr" rid="article-30349.r14">[14]</xref>&#x000a0;</p>
        <p>Significant life-threatening&#x000a0;complications include serotonin syndrome, cardiac dysrhythmias, rhabdomyolysis, disseminated intravascular coagulation, aortic dissection, and intracranial hemorrhages.<xref ref-type="bibr" rid="article-30349.r8">[8]</xref><xref ref-type="bibr" rid="article-30349.r20">[20]</xref><xref ref-type="bibr" rid="article-30349.r21">[21]</xref>&#x000a0;Since MDMA undergoes metabolism via hepatic CYP2D6, severe hepatoxicity&#x000a0;may occur, leading to fulminant liver failure.<xref ref-type="bibr" rid="article-30349.r22">[22]</xref>&#x000a0;&#x000a0;Central nervous system (CNS)&#x000a0;hyperactivity can lead to agitated delirium and seizures.<xref ref-type="bibr" rid="article-30349.r23">[23]</xref><xref ref-type="bibr" rid="article-30349.r24">[24]</xref>&#x000a0;</p>
        <p>Because&#x000a0;MDMA is a popular rave drug, the combination of intense physical activity with the sympathomimetic effects of the drug leads to an increase in body temperature that resembles heat stroke and&#x000a0;could result in rhabdomyolysis.<xref ref-type="bibr" rid="article-30349.r25">[25]</xref>&#x000a0;Significant increases in fluid consumption by users coupled with the development of the syndrome of inappropriate diuretic syndrome (SIADH)&#x000a0;may potentially contribute to the development of severe hyponatremia, leading to cerebral edema, seizures, and death.<xref ref-type="bibr" rid="article-30349.r26">[26]</xref><xref ref-type="bibr" rid="article-30349.r27">[27]</xref></p>
      </sec>
      <sec id="article-30349.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic testing should be guided by the clinical presentation (history and physical exam). Initially, evaluation of the altered patient must include intravenous (IV) access, vital signs, rapid glucose check, and complete physical examination. Obtaining a core body temperature (rectal or bladder) is critical to diagnose life-threatening hyperthermia (&#x0003e;105 &#x000b0;F or &#x0003e;40.5 &#x000b0;C).&#x000a0;</p>
        <p>Recommended lab tests are as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Basic metabolic panel (BMP) to evaluate for:
<list list-type="bullet"><list-item><p>Electrolyte abnormalities such as hyponatremia and hyperkalemia</p></list-item><list-item><p>Acute kidney injury - blood urea nitrogen (BUN) and creatinine (Cr) levels</p></list-item><list-item><p>Rhabdomyolysis - creatine phosphokinase (CPK) levels</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Liver function tests (LFTs)&#x000a0;to evaluate fulminant hepatic failure</p>
          </list-item>
          <list-item>
            <p>Electrocardiogram (EKG) for screening tachyarrhythmias</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC), urinalysis, coagulation profile, chest radiography, computed tomography (CT) head scan, or lumbar puncture in the undifferentiated altered mental status patient</p>
          </list-item>
          <list-item>
            <p>Qualitative urine immunoassays (urine drug screens) for amphetamines&#x000a0;should&#x000a0;not guide the clinical management of patients. The major limitation of&#x000a0;amphetamine immunoassays&#x000a0;is the high rate of false positives and false negatives. An actual positive result means that the patient used a certain amphetamine within the past several days and&#x000a0;did not distinguish acute or recent use. The&#x000a0;gold standard of drug testing, gas chromatography-mass spectrometry analysis, may misidentify isomeric substances such as <italic toggle="yes">l</italic>-methamphetamine (present in nasal inhalers) versus <italic toggle="yes">d</italic>-methamphetamine.&#x000a0;
<list list-type="bullet"><list-item><p>Xenobiotics that cause false-positive qualitative amphetamine screens include pseudoephedrine, L-ephedrine, procainamide, mexiletine, selegiline, bupropion, trazodone, and amantadine.</p></list-item><list-item><p>Xenobiotics known to cause false negatives include MDMA&#x000a0;and cathinones.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30349.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial management includes continuous cardiac monitoring, maintaining&#x000a0;a patent airway, and&#x000a0;prioritizing breathing&#x000a0;and circulation. For the agitated patient, temporary physical restraints may&#x000a0;help gain pharmacologic control. They should be discontinued as soon as possible to avoid the development or worsening of rhabdomyolysis and heat generation. A core temperature (rectally or bladder) greater than 105 &#x000b0;F (40.5 &#x000b0;C) represents rapid life-threatening hyperthermia and takes precedence after initial airway evaluation.<xref ref-type="bibr" rid="article-30349.r25">[25]</xref>&#x000a0;Treatment of hyperthermia involves both rapid sedation to control agitation and external cooling. External cooling with whole-body ice-water immersion is effective for treating life-threatening hyperthermia.<xref ref-type="bibr" rid="article-30349.r28">[28]</xref><xref ref-type="bibr" rid="article-30349.r29">[29]</xref><xref ref-type="bibr" rid="article-30349.r30">[30]</xref>&#x000a0;</p>
        <p>Sedation with&#x000a0;IV benzodiazepines such as diazepam (10 mg) or lorazepam (2 mg) is the first-line treatment for agitation secondary to acute amphetamine toxicity.<xref ref-type="bibr" rid="article-30349.r31">[31]</xref>&#x000a0; The predictable pharmacokinetics, high therapeutic index, and anti-epileptic activity of benzodiazepines make for an&#x000a0;effective treatment for undifferentiated agitated patients. If IV access is unavailable, intramuscular doses of midazolam are effective. Sedation should be titrated rapidly until the patient is calm.<xref ref-type="bibr" rid="article-30349.r32">[32]</xref></p>
        <p>Rhabdomyolysis from acute amphetamine toxicity occurs from psychomotor agitation and hyperthermia. Supportive care with&#x000a0;IV hydration should maintain a urine output of at least 1 to 2 mL/kg/h. Urine acidification may increase elimination and decrease the half-life of amphetamines. Still, it is not recommended since it does not decrease toxicity and increases the risk of acute kidney injury (AKI) from rhabdomyolysis.<xref ref-type="bibr" rid="article-30349.r33">[33]</xref><xref ref-type="bibr" rid="article-30349.r34">[34]</xref>&#x000a0;Hemodialysis may be required in patients with renal failure, severe acidemia, and hyperkalemia.&#x000a0;Given the limited evidence and potential harms, dantrolene is not recommended to treat amphetamine-induced hyperthermia.<xref ref-type="bibr" rid="article-30349.r35">[35]</xref> &#x000a0;</p>
      </sec>
      <sec id="article-30349.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses include the following:</p>
        <list list-type="order">
          <list-item>
            <p>Anticholinergic toxicity</p>
          </list-item>
          <list-item>
            <p>Cholinergic toxicity</p>
          </list-item>
          <list-item>
            <p>Neuroleptic malignant syndrome</p>
          </list-item>
          <list-item>
            <p>Malignant hyperthermia</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome</p>
          </list-item>
          <list-item>
            <p>Monoamine oxidase inhibitor toxicity</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Heatstroke</p>
          </list-item>
          <list-item>
            <p>Heat exhaustion</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Amphetamine toxicity</p>
          </list-item>
          <list-item>
            <p>Cocaine toxicity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30349.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The&#x000a0;2 most frequently reported causes of death include hyperthermia and hyponatremia. While toxicity can be severe, a literature review reveals deaths related to MDMA toxicity&#x000a0;are&#x000a0;rare. Confounding factors include co-ingested drugs,&#x000a0;making it challenging to&#x000a0;determine if&#x000a0;MDMA&#x000a0;was the&#x000a0;cause of death.</p>
        <p>Though deaths are rare, animal and radiological studies have demonstrated the potential for long-term&#x000a0;adverse effects.&#x000a0;In MDMA-treated monkeys,&#x000a0;a loss of serotonin axon terminal markers was observed,&#x000a0;leading to deficits in emotion, memory, and high-order cognitive processes. Positron emission tomography (PET) scans in baboons showed significant decreases in radioactivity levels in various brain areas. Similarly, human volunteers with a history of MDMA use underwent PET scanning and were found to have a global dose-related reduction in a structural element of serotonin. Further studies on PET scans of volunteers with a history of MDMA abuse showed similar effects, along with changes in the amygdala and neocortex regions. Deficits in short-term memory, visual memory, verbal memory, and reasoning seem to be associated. The cerebrovascular systems may also be affected, causing a decline in cognitive abilities that can resemble dementia.<xref ref-type="bibr" rid="article-30349.r36">[36]</xref><xref ref-type="bibr" rid="article-30349.r37">[37]</xref></p>
      </sec>
      <sec id="article-30349.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of MDMA toxicity include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic complications include delirium and seizures&#x000a0;<xref ref-type="bibr" rid="article-30349.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiovascular complications include cardiac dysrhythmias, myocardial infarction, aortic dissection, and intracranial hemorrhages&#x000a0;<xref ref-type="bibr" rid="article-30349.r8">[8]</xref><xref ref-type="bibr" rid="article-30349.r20">[20]</xref><xref ref-type="bibr" rid="article-30349.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Gastrointestinal complications include severe hepatotoxicity, which can lead to fulminant liver failure&#x000a0;<xref ref-type="bibr" rid="article-30349.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Renal complications include rhabdomyolysis and acute renal failure&#x000a0;<xref ref-type="bibr" rid="article-30349.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Endocrine complications include the development of a syndrome of inappropriate diuretic hormone (SIADH), resulting in life-threatening hyponatremia and seizures</p>
          </list-item>
          <list-item>
            <p>Patients can also present with life-threatening hyperthermia mimicking heat stroke&#x000a0;<xref ref-type="bibr" rid="article-30349.r25">[25]</xref><xref ref-type="bibr" rid="article-30349.r26">[26]</xref><xref ref-type="bibr" rid="article-30349.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Other&#x000a0;complications include increased psychomotor agitation or muscle activity (such as bruxism, restless legs, and jaw clenching), hyperactivity, insomnia, difficulty concentrating, and feelings of restlessness&#x000a0;<xref ref-type="bibr" rid="article-30349.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30349.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is crucial in helping patients understand both the short- and long-term risks associated with MDMA use. Many users incorrectly perceive MDMA&#x000a0;as a safe drug with few adverse effects. Tolerance develops rapidly, and&#x000a0;those who respond by&#x000a0;ingesting larger doses&#x000a0;are at risk for complications&#x000a0;that include sympathetic hyperactivity, potentially resulting in hyperthermia,&#x000a0;arrhythmias, and hemodynamic instability.</p>
        <p>Patients must also&#x000a0;understand the long-term psychiatric implications that accompany&#x000a0;regular use. There are reports of depression, paranoia, anxiety, and insomnia&#x000a0;lasting&#x000a0;years&#x000a0;following cessation of MDMA use. Additionally,&#x000a0;research shows&#x000a0;correlations between MDMA use and impaired concentration and memory.<xref ref-type="bibr" rid="article-30349.r38">[38]</xref></p>
      </sec>
      <sec id="article-30349.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MDMA toxicity can be life-threatening and involve multiple organ systems, necessitating an interprofessional approach. Providers need to be prepared to treat potential toxicities because treatment is mainly supportive. This requires an interprofessional team approach to managing toxicity, including education, interventions, monitoring, and follow-up from all disciplines,&#x000a0;particularly emergency clinicians, toxicology specialists, mid-level practitioners, nurses, pharmacists, and mental health professionals. By coordinating activities and sharing information, the patient is more likely to achieve successful short- and long-term outcomes.</p>
        <p>The most effective solution to the issue at hand is prevention. According to existing literature,&#x000a0;MDMA use is often motivated by curiosity, availability, affordability, and a desire to enhance mood and social interaction due to social influence.<xref ref-type="bibr" rid="article-30349.r39">[39]</xref>&#x000a0;It is crucial to educate vulnerable populations about the harmful effects of MDMA to reduce its usage.</p>
      </sec>
      <sec id="article-30349.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30349&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30349">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/addiction/34-methylenedioxymethamphetamine-mdma-toxicity-ecstasy-molly-overdose/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30349">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30349/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30349">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30349.s16">
        <title>References</title>
        <ref id="article-30349.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ot'alora G</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Kolk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bogenschutz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Paleos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Quevedo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balliett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mithoefer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parker-Guilbert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tzarfaty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doblin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yazar-Klosinski</surname>
                <given-names>B</given-names>
              </name>
              <collab>MAPP2 Study Collaborator Group</collab>
            </person-group>
            <article-title>MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.</article-title>
            <source>Nat Med</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>2473</fpage>
            <page-range>2473-2480</page-range>
            <pub-id pub-id-type="pmid">37709999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Benzenh&#x000f6;fer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>The History of MDMA as an Underground Drug in the United States, 1960-1979.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2016</year>
            <season>Apr-Jun</season>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-75</page-range>
            <pub-id pub-id-type="pmid">26940772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hysek</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Simmler</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Schillinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Donzelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grouzmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liechti</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-81</page-range>
            <pub-id pub-id-type="pmid">24103254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parrott</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.</article-title>
            <source>J Psychopharmacol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-63</page-range>
            <pub-id pub-id-type="pmid">16510474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parrott</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.</article-title>
            <source>J Psychopharmacol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-83</page-range>
            <pub-id pub-id-type="pmid">15671132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Repetto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jurado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gim&#x000e9;nez</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Men&#x000e9;ndez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose.</article-title>
            <source>Forensic Sci Int</source>
            <year>2003</year>
            <month>Aug</month>
            <day>12</day>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-4</page-range>
            <pub-id pub-id-type="pmid">12927411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traub</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine.</article-title>
            <source>J Urban Health</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-55</page-range>
            <pub-id pub-id-type="pmid">12468674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>3,4-methylenedioxymethamphetamine (MDMA): current perspectives.</article-title>
            <source>Subst Abuse Rehabil</source>
            <year>2013</year>
            <volume>4</volume>
            <fpage>83</fpage>
            <page-range>83-99</page-range>
            <pub-id pub-id-type="pmid">24648791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiyatkin</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clubbing with ecstasy.</article-title>
            <source>Temperature (Austin)</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>160</fpage>
            <page-range>160-1</page-range>
            <pub-id pub-id-type="pmid">27627800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wish</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Fitzelle</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Arria</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Evidence for significant polydrug use among ecstasy-using college students.</article-title>
            <source>J Am Coll Health</source>
            <year>2006</year>
            <season>Sep-Oct</season>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-104</page-range>
            <pub-id pub-id-type="pmid">17017306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leshner</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Ecstasy abuse and control: hearing before the Senate Subcommittee on Governmental Affairs--July 30, 2001. Statement for the record.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2002</year>
            <season>Apr-Jun</season>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-5</page-range>
            <pub-id pub-id-type="pmid">12691202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Parrott</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ringwalt</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions.</article-title>
            <source>Am J Addict</source>
            <year>2009</year>
            <season>Nov-Dec</season>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>452</fpage>
            <page-range>452-61</page-range>
            <pub-id pub-id-type="pmid">19874166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Benzenh&#x000f6;fer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s).</article-title>
            <source>Drug Test Anal</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-80</page-range>
            <pub-id pub-id-type="pmid">28851034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vollenweider</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Gamma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liechti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-na&#x000ef;ve healthy volunteers.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-51</page-range>
            <pub-id pub-id-type="pmid">9718588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parrott</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2004</year>
            <month>May</month>
            <volume>173</volume>
            <issue>3-4</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">15007594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moritz</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ayus</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Ecstacy-associated hyponatremia: why are women at risk?</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>2206</fpage>
            <page-range>2206-9</page-range>
            <pub-id pub-id-type="pmid">23804804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farr&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de la Torre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roset</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Ortu&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Segura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cam&#x000ed;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>290</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-45</page-range>
            <pub-id pub-id-type="pmid">10381769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Otton</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kalow</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Interactions of amphetamine analogs with human liver CYP2D6.</article-title>
            <source>Biochem Pharmacol</source>
            <year>1997</year>
            <month>Jun</month>
            <day>01</day>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>1605</fpage>
            <page-range>1605-12</page-range>
            <pub-id pub-id-type="pmid">9264312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Souza</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Battaglia</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effects of MDMA and MDA on brain serotonin neurons: evidence from neurochemical and autoradiographic studies.</article-title>
            <source>NIDA Res Monogr</source>
            <year>1989</year>
            <volume>94</volume>
            <fpage>196</fpage>
            <page-range>196-222</page-range>
            <pub-id pub-id-type="pmid">2575225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction.</article-title>
            <source>Ann Emerg Med</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>759</fpage>
            <page-range>759-62</page-range>
            <pub-id pub-id-type="pmid">14634599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duflou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Aortic dissection after ingestion of "ecstasy" (MDMA).</article-title>
            <source>Am J Forensic Med Pathol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-3</page-range>
            <pub-id pub-id-type="pmid">10990289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lange-Brock</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Fliege</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klapp</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>M&#x000f6;nnikes</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Acute liver failure following the use of ecstasy (MDMA)].</article-title>
            <source>Z Gastroenterol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>581</fpage>
            <page-range>581-6</page-range>
            <pub-id pub-id-type="pmid">12297982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Theune</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esser</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Druschky</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Interschick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patscheke</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Grand mal series after Ecstasy abuse].</article-title>
            <source>Nervenarzt</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>1094</fpage>
            <page-range>1094-7</page-range>
            <pub-id pub-id-type="pmid">10637815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shokry</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Callanan</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.</article-title>
            <source>Ann Forensic Res Anal</source>
            <year>2017</year>
            <volume>4</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29732414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginsberg</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hertzman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt-Nowara</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke.</article-title>
            <source>Ann Intern Med</source>
            <year>1970</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-5</page-range>
            <pub-id pub-id-type="pmid">5433281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthai</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Sills</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Alexandrou</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water.</article-title>
            <source>BMJ</source>
            <year>1996</year>
            <month>May</month>
            <day>25</day>
            <volume>312</volume>
            <issue>7042</issue>
            <fpage>1359</fpage>
            <pub-id pub-id-type="pmid">8646063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cluroe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Synek</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use.</article-title>
            <source>N Z Med J</source>
            <year>1999</year>
            <month>Jul</month>
            <day>09</day>
            <volume>112</volume>
            <issue>1091</issue>
            <fpage>255</fpage>
            <page-range>255-6</page-range>
            <pub-id pub-id-type="pmid">10448984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lindquist</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>A body bag can save your life: a novel method of cold water immersion for heat stroke treatment.</article-title>
            <source>J Am Coll Emerg Physicians Open</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-52</page-range>
            <pub-id pub-id-type="pmid">33000014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Stimulant-induced hyperthermia and ice-water submersion: Practical considerations.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2016</year>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-70</page-range>
            <pub-id pub-id-type="pmid">26515112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laskowski</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Ice water submersion for rapid cooling in severe drug-induced hyperthermia.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-4</page-range>
            <pub-id pub-id-type="pmid">25695144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derlet</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Albertson</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antagonism of cocaine, amphetamine, and methamphetamine toxicity.</article-title>
            <source>Pharmacol Biochem Behav</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-9</page-range>
            <pub-id pub-id-type="pmid">2217500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grundlingh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>MDMA toxicity: management of acute and life-threatening presentations.</article-title>
            <source>Br J Nurs</source>
            <year>2018</year>
            <month>Jun</month>
            <day>14</day>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>616</fpage>
            <page-range>616-622</page-range>
            <pub-id pub-id-type="pmid">29894255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beckett</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The amphetamines: clinical and pharmacokinetic implications of recent studies of an assay procedure and urinary excretion in man.</article-title>
            <source>Arzneimittelforschung</source>
            <year>1966</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1369</fpage>
            <page-range>1369-73</page-range>
            <pub-id pub-id-type="pmid">4880484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Influences of urinary pH on the pharmacokinetics of three amphetamine-type stimulants using a new high-performance liquid chromatographic method.</article-title>
            <source>J Pharm Sci</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>728</fpage>
            <page-range>728-38</page-range>
            <pub-id pub-id-type="pmid">18481797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunau</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wiens</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Brubacher</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review.</article-title>
            <source>CJEM</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <page-range>435-42</page-range>
            <pub-id pub-id-type="pmid">20880437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Does recreational ecstasy use cause long-term cognitive problems?</article-title>
            <source>West J Med</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>173</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-30</page-range>
            <pub-id pub-id-type="pmid">10924441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ricaurte</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Scheffel</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').</article-title>
            <source>Toxicol Lett</source>
            <year>2000</year>
            <month>Mar</month>
            <day>15</day>
            <volume>112-113</volume>
            <fpage>143</fpage>
            <page-range>143-6</page-range>
            <pub-id pub-id-type="pmid">10720723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Figurasin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <chapter-title>3,4-Methylenedioxymethamphetamine (MDMA) Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30860717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30349.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A structured review of reasons for ecstasy use and related behaviours: pointers for future research.</article-title>
            <source>BMC Public Health</source>
            <year>2009</year>
            <month>Jul</month>
            <day>13</day>
            <volume>9</volume>
            <fpage>230</fpage>
            <pub-id pub-id-type="pmid">19594926</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
